Therefore, enhancing CMA activity or preventing the arrival of toxic forms of tau to CMA-active lysosomes, or promoting degradation of rerouted tau inside LE/MVB could all be fruitful options to prevent neurodegeneration in AD and other tauopathies. The gene discussed is MAPT; the disease is Alzheimer disease.